Deciphera Pharmaceuticals Statistics
Share Statistics
Deciphera Pharmaceuticals has 86.48M
shares outstanding. The number of shares has increased by 0%
in one year.
| Shares Outstanding | 86.48M |
| Shares Change (YoY) | 0% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | n/a |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 1,305 |
| FTD / Avg. Volume | 0.07% |
Short Selling Information
The latest short interest is 3.17M, so 3.67% of the outstanding
shares have been sold short.
| Short Interest | 3.17M |
| Short % of Shares Out | 3.67% |
| Short % of Float | 5.12% |
| Short Ratio (days to cover) | 2.79 |
Valuation Ratios
The PE ratio is -7.04 and the forward
PE ratio is null.
Deciphera Pharmaceuticals's PEG ratio is
2.09.
| PE Ratio | -7.04 |
| Forward PE | n/a |
| PS Ratio | 8.4 |
| Forward PS | n/a |
| PB Ratio | 3.91 |
| P/FCF Ratio | -9.3 |
| PEG Ratio | 2.09 |
Financial Ratio HistoryEnterprise Valuation
Deciphera Pharmaceuticals has an Enterprise Value (EV) of 1.31B.
| EV / Sales | 8.05 |
| EV / EBITDA | -6.29 |
| EV / EBIT | -8.96 |
| EV / FCF | -8.91 |
Financial Position
The company has a current ratio of 3.8,
with a Debt / Equity ratio of 0.07.
| Current Ratio | 3.8 |
| Quick Ratio | 3.59 |
| Debt / Equity | 0.07 |
| Debt / EBITDA | -0.12 |
| Debt / FCF | -0.18 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is -55.55% and Return on Invested Capital is -56.11%.
| Return on Equity | -55.55% |
| Return on Assets | -41.16% |
| Return on Invested Capital | -56.11% |
| Revenue Per Employee | $460,157.75 |
| Profits Per Employee | $-549,132.39 |
| Employee Count | 355 |
| Asset Turnover | 0.34 |
| Inventory Turnover | 0.18 |
Taxes
| Income Tax | 431K |
| Effective Tax Rate | -0.22% |
Stock Price Statistics
The stock price has increased by 75.03% in the
last 52 weeks. The beta is 0.18, so Deciphera Pharmaceuticals's
price volatility has been higher than the market average.
| Beta | 0.18 |
| 52-Week Price Change | 75.03% |
| 50-Day Moving Average | 21.46 |
| 200-Day Moving Average | 15.86 |
| Relative Strength Index (RSI) | 85.58 |
| Average Volume (20 Days) | 1,855,995 |
Income Statement
In the last 12 months, Deciphera Pharmaceuticals had revenue of 163.36M
and earned -194.94M
in profits. Earnings per share was -2.29.
| Revenue | 163.36M |
| Gross Profit | 159.62M |
| Operating Income | -210.96M |
| Net Income | -194.94M |
| EBITDA | -208.86M |
| EBIT | n/a |
| Earnings Per Share (EPS) | -2.29 |
Full Income StatementBalance Sheet
The company has 83.51M in cash and 25.88M in
debt, giving a net cash position of 57.63M.
| Cash & Cash Equivalents | 83.51M |
| Total Debt | 25.88M |
| Net Cash | 57.63M |
| Retained Earnings | -1.43B |
| Total Assets | 420.93M |
| Working Capital | 266.51M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -146.7M
and capital expenditures -778K, giving a free cash flow of -147.47M.
| Operating Cash Flow | -146.7M |
| Capital Expenditures | -778K |
| Free Cash Flow | -147.47M |
| FCF Per Share | -1.73 |
Full Cash Flow StatementMargins
Gross margin is 97.72%, with operating and profit margins of -129.14% and -119.34%.
| Gross Margin | 97.72% |
| Operating Margin | -129.14% |
| Pretax Margin | -119.07% |
| Profit Margin | -119.34% |
| EBITDA Margin | -127.85% |
| EBIT Margin | -129.14% |
| FCF Margin | -90.28% |
